Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates - PubMed (original) (raw)

Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates

S W Wright et al. J Gen Intern Med. 1999 Oct.

Abstract

Objective: A large majority of urinary tract infections are caused by coliform organisms. Trimethoprim-sulfamethoxazole (TMP-SMX) resistance among uropathogens is increasing in many areas. The objective of this study was to determine risk factors for TMP-SMX-resistant coliforms in patients with urinary tract infections.

Design: Retrospective case-control study.

Setting: Emergency department of a tertiary care university hospital.

Patients: We studied 448 emergency department patients aged 14 years or older with a urinary tract infection caused by a coliform organism. Cases consisted of all patients with a culture-documented urinary tract infection caused by a TMP-SMX-resistant coliform, while control patients were those with a TMP-SMX-sensitive organism.

Measurements and main results: A univariate analysis of clinical variables associated with TMP-SMX resistance was performed. Multiple logistic regression was performed to determine independent predictors of TMP-SMX resistance. Resistance to TMP-SMX was seen in 15% of isolates. Numerous variables were associated with TMP-SMX resistance on the univariate screen. Independent predictors of resistance were diabetes (odds ratio [OR] 3.1; 95% confidence interval [CI] 1.2, 8.4), recent hospitalization (OR 2.5; 95% CI 1.1, 5.7), current use of antibiotics (OR 4.5; 95% CI 2.0, 10.2), and recent use of TMP-SMX (OR 5.1; 95% CI 2.2, 11.5). When those with recent hospitalization were excluded from analysis, independent predictors were current use of any antibiotic (OR 3.5; 95% CI 1.4, 8. 4) and recent use of TMP-SMX (OR 5.9; 95% CI 2.4, 14.3).

Conclusions: Coliforms resistant to TMP-SMX are common in our emergency department. Diabetes, recent hospitalization, and the use of antibiotics, particularly the use of TMP-SMX, are independent risk factors for TMP-SMX resistance. Clinicians should consider these findings when deciding on antimicrobial therapy for patients with urinary tract infections.

PubMed Disclaimer

Comment in

References

    1. Levy SB. Confronting multidrug resistance: a role for each of us. JAMA. 1993;269:1840–2. -PubMed
    1. Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA. 1996;275:300–4. -PubMed
    1. Hoffman J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333:481–6. -PubMed
    1. Stamm WE, Hooton TM. Management of urinary tract infection in adults. N Engl J Med. 1993;329:1328–34. -PubMed
    1. Marco CA, Parker K. Antimicrobial resistance among organisms causing urinary tract infection. Acad Emerg Med. 1997;4:159–60. -PubMed

MeSH terms

Substances

LinkOut - more resources